Lung cancer remains the biggest cancer killer in Europe, accounting for approximately 20% of all cancer deaths. Yet, in recent years, several advances have been made in standards of care, personalised therapies, including immunotherapies and advances in diagnostics.
This year's Congress programme has a considerable variety of oncology-focussed activities including sessions, skills workshops, symposia, postgraduate courses, hot topic sessions, poster discussions, oral presentations, challenging clinical cases and meetings covering the most up-to-date developments in the field.
Chair of the ERS Thoracic Oncology Assembly Nicolas Schönfeld, highlighted: "The field of lung cancer is seeing several exciting changes that are leading the way in terms of treatments for all cancers. Immunotherapy developments are particularly exciting and a number of abstracts will be presented at the ERS Congress sharing the latest research in this field. I see this as a wonderful opportunity for not only assembly members, but all respiratory healthcare professionals interested in this field to learn what's new and where the next steps in targeted lung cancer therapies may take us."
Are you interested in joining the ERS Thoracic Oncology Assembly? You can do so on MyERS.
If you are interested in this topic, here is a list of associated sessions at this year's Congress. Alternatively, you can browse the full programme and filter your search by the 'Oncology' track for more sessions on this topic.
Note: Educational sessions (postgraduate courses, skills workshops, challenging clinical cases, professional development workshops and meet the expert sessions) can be attended at an additional cost to the standard registration fee.